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Abstract
Background—Identifying sexually transmitted infections (STI) in HIV-infected individuals has 
potential to benefit individual and public health. There are few guidelines regarding routine STI 
screening in sub-Saharan African HIV programs. We determined sexual risk behavior and 
prevalence and correlates of STI in a national survey of large HIV treatment programs in Kenya.
Methods—A mobile screening team visited 39 (95%) of the 42 largest HIV care programs in 
Kenya and enrolled participants using population-proportionate systematic sampling. Participants 
provided behavioral and clinical data. Genital and blood specimens were tested for trichomoniasis, 
gonorrhea, chlamydia, syphilis, and CD4 T-lymphocyte counts.
Results—Among 1661 adults, 41% reported no sexual partners in the past 3 months. Among 
those who reported sex in the past 3 months, 63% of women reported condom use during this 
encounter compared with 77% of men (P < 0.001). Trichomoniasis was the most common STI in 
Correspondence: Grace John-Stewart, MD, PhD, University of Washington, Harborview Medical Center, 325 9th Ave, Box 359909, 
Seattle, WA 98104. gjohn@u.washington.edu.
Sara Nelson Glick contributed equally to the manuscript.
The authors state no conflicts of interest.
Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the US 
Centers for Disease Control and Prevention. The use of trade names is for identification purposes only and does not constitute 
endorsement by the US Centers for Disease Control and Prevention or the Department of Health and Human Services.
Author contributions: Sara Nelson Glick, Benson Singa, Naomi Bock, and Grace John-Stewart conceptualized the present analysis. 
Sara Nelson Glick conducted the statistical analyses and wrote the manuscript. Grace John-Stewart and Naomi Bock conceptualized 
and designed the study and obtained funding. Benson Singa and Gaston Djomand designed study procedures, and Benson Singa 
oversaw field implementation of the study procedures. Judd Walson, James Odek, and R. Scott McClelland contributed to the design, 
conduct, and interpretation of study results. Linda Chaba and Hongjiang Gao provided data management and statistical analysis 
support. All authors contributed reviewed, edited, and approved the final version of this article.
HHS Public Access
Author manuscript
Sex Transm Dis. Author manuscript; available in PMC 2016 June 14.
Published in final edited form as:













women (10.9%) and men (2.8%); prevalences of gonorrhea, chlamydia, and syphilis were low 
(<1%–2%). Among women, younger age (adjusted odds ratio [OR], 0.96 per year; 95% 
confidence interval [CI], 0.94–0.98) and primary school education or lower level (adjusted OR, 
2.16; 95% CI, 1.37–3.40) were independently associated with trichomoniasis, whereas CD4 count, 
cotrimoxazole use, and reported condom use were not. Reported condom use at last sex was 
associated with reporting that the clinic provided condoms among both women (OR, 1.7; 95% CI, 
1.17–2.35) and men (OR, 2.4; 95% CI, 1.18–4.82).
Conclusions—Women attending Kenyan HIV care programs had a 10.9% prevalence of 
trichomoniasis, suggesting that screening for this infection may be useful. Condom provision at 
clinics may enhance secondary HIV prevention efforts.
Treating sexually transmitted infections (STI) in HIV-infected individuals has potential to 
benefit both individual and public health.1 Some STIs may have increased incidence among 
HIV-infected compared with HIV-uninfected individuals.2 Sexually transmitted infections 
have been associated with increased genital HIV viral load,3–8 and observational data 
suggest that STIs facilitate HIV transmission.9 Researchers have hypothesized that 
preventing and treating STIs would reduce HIV incidence at population level. However, 
among 9 large trials investigating the effect of STI treatment on HIV incidence, only 1 
demonstrated a significant reduction.10 Thus, some have questioned the importance of STI 
programs for HIV prevention,11 whereas others suggest that trial design, insufficient power, 
HIV epidemic phase, and STI prevalence explain null findings in these trials and that STI 
treatment should remain an HIV prevention tool.12
World Health Organization (WHO) guidelines recommend that STI assessment and 
treatment be an integral part of a comprehensive HIV strategy to improve the health of HIV 
patients, their partners, and families, as well as to reduce spread of HIV.13 Specifically, 
individuals newly diagnosed as having HIV should be asked about STI symptoms and 
receive laboratory screening for syphilis. When feasible, women should also receive testing 
for gonorrhea and chlamydial infection. Patients diagnosed as having an STI, as well as their 
sex partners, should receive treatment according to current guidelines. The role of further 
routine STI screening for individuals in HIV care programs is less clear.
The World Health Organization recommends that countries conduct national STI prevalence 
assessments every 3 to 5 years to inform STI treatment guidelines. These surveys, however, 
are expensive and rarely conducted in resource-constrained settings. The United States 
supports HIV programs through the President’s Emergency Plan for AIDS Relief. In Kenya 
in 2010, this funding was used to provide care to more than 1.3 million HIV-infected 
individuals, including antiretroviral therapy (ART) to more than 400,000.14 ART 
significantly decreases sexual HIV transmission, as most clearly demonstrated by the HIV 
Prevention Trials Network 052 study.15 However, STIs may alter genital viral load despite 
ART making STI screening in HIV programs potentially beneficial for individuals and for 
secondary prevention.16
To inform large HIV care programs about the potential use of routine STI screening, we 
conducted a national surveillance study in Kenya to assess the burden of STI among HIV-
infected adults in HIV care programs. Our aims were to estimate STI prevalence in adults in 
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HIV programs throughout Kenya, to determine recent sexual risk behavior, and identify 
cofactors associated with prevalent STI.
MATERIALS AND METHODS
Study Design and Sampling Framework
To recruit a representative sample of HIV programs with sufficient sample size to estimate 
STI prevalence, we conducted population-proportionate sampling of clinics. The number of 
patients on ART served as a proxy for clinic size. Of 321 clinics with more than 50 ART 
clients, the largest 42 were selected (all >1600 clients on ART). We recruited participants 
from 39 of these clinics: 2 of the original clinics had combined, 1 refused to participate, and 
1 was inaccessible to the field team. These clinics were located in 7 of Kenya’s 8 provinces 
and accounted for an estimated 12% of all Kenyan HIV clinics and 51% of all ART clients.
Eligibility and Study Procedures
Four mobile study teams enrolled participants between February and September 2010. 
Participants were eligible if they were HIV infected, receiving care at one of the selected 
clinics, 18 years or older, and able and willing to provide informed consent. Because study 
procedures involved taking a vaginal swab, we excluded pregnant women who were more 
than 36 weeks’ gestation.
The number of patients enrolled per site was proportionate to the number of registered 
patients receiving ART at that clinic. An initial sample size of 1600 was allocated 
proportionate to the number of adults on ART across the study sites. Several small sites were 
oversampled to achieve a minimum sample size of 30 per site, and 1 very large site was 
oversampled for a final target sample size of 1780. Patients were systematically approached 
(i.e., every nth patient) and offered screening for eligibility. If a patient was eligible and 
consented, a trained study nurse administered a structured questionnaire, assessed the 
patient’s current STI symptoms, conducted a physical examination of the external genitalia, 
and collected specimens for laboratory testing. Study staff collected survey and clinic data 
on standardized paper forms and entered data into a Web-based database.
When symptoms and signs were present, the study nurse made a syndromic STI diagnosis 
and provided immediate treatment based on the current Kenya Ministry of Health guidelines. 
Once laboratory results were available, participants who were asymptomatic but diagnosed 
etiologically were called and asked to return to clinic for appropriate treatment. Participants 
who received STI treatment were given a referral card for their partners to seek STI care and 
HIV testing.
The study was approved by the institutional review boards of the 3 collaborating institutions 
including the Kenya Medical Research Institute, the University of Washington, and the US 
Centers for Disease Control and Prevention.
Survey Measures
The survey included questions about sociodemographic information, recent sexual risk 
behaviors, and HIV/medical history. We chose a subset of measures, a priori, as potential 
Singa et al. Page 3













correlates of STI. Sociodemographic data included age, current marital status, education 
level, and the province in which the clinic was located. Participants indicated the number of 
sexual partners in the past 3 months, and if they reported 1 or more partners, they were asked 
a series of questions about each of their most recent partners (up to 3). These questions 
included whether the partner was a spouse (including polygamous marriages) or other type 
of partner, if last sex occurred within the past week or not, and whether or not a condom was 
used during the last sexual encounter. Participants also reported if their clinic provided 
condoms. Finally, we asked participants about when they were diagnosed as having HIV, 
current ART use, and current cotrimoxazole use.
Specimens and Laboratory Testing
We tested for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and 
Treponema pallidum. Men provided a first-catch urine specimen, whereas women had 
vaginal swabs collected. Genital ulcer swabs were collected from participants with genital 
ulcers and tested for herpes simplex virus (HSV) 1, HSV-2, and T. pallidum. All participants 
had blood drawn for syphilis serology and CD4 T-lymphocyte counts.
First-catch urine and vaginal swab specimens were tested for C. trachomatis and N. 
gonorrhoeae by transcription-mediated amplification using the Gen-Probe APTIMA Combo 
2GC/CT system; the Gen-Probe transcription-mediated amplification system was also used 
to test for the presence of T. vaginalis. We screened for syphilis using rapid plasma reagin 
assays for screening and T. pallidum hemagglutination assays for confirmation. For this 
analysis, participants with positive rapid plasma reagin and T. pallidum hemagglutination 
assay were categorized as having active syphilis. Real-time multiplex polymerase chain 
reaction was used to detect HSV-1, HSV-2, and T. pallidum from genital ulcers. CD4 T-
lymphocyte counts were assessed using FACSCalibur.
Statistical Analysis
Our analyses were designed, first, to estimate STI prevalence; second, to determine cofactors 
for STIs; and third, to provide sexual behavior data useful for secondary prevention 
programs. We compared sociodemographic, sexual behavior, and health-related differences 
between women and men using χ2 tests. Similarly, we calculated and compared the sex-
specific counts and prevalences of individual STI. We weighted all estimates to reflect 
selection probability of each study site, and study site was also included in the data analysis 
to account for cluster effect. The study was powered to provide national estimates of 
prevalence of 4.5%, with 95% confidence intervals (CIs) of ±1.5%. Only trichomoniasis 
among women reached the 4.5% prevalence threshold; thus, we explored the bivariate 
correlates of trichomoniasis diagnosis among women using logistic regression and reported 
the corresponding odds ratios (ORs) and 95% CIs. Age was modeled as a continuous 
variable and education dichotomized. We further selected all variables in bivariate analysis 
with a P value of 0.10 or less and conducted a multiple logistic regression to assess the 
adjusted correlates between trichomoniasis and those variables. All analyses were conducted 
using Intercooled Stata 12 (College Station, TX).
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Of 1942 participants approached to participate, 281 (14%) declined participation and 1,661 
(86%) were eligible, consented, and enrolled. As shown in Table 1, nearly two thirds 
(63.9%) were female, and women were younger, were less likely to be married, and had less 
education compared with men. The median age was 35 years (range, 18–70 years) among 
women and 40 years (range, 18–77 years) among men. Approximately 40% reported no 
sexual partners in the past 3 months, and this was significantly more common in women 
compared with men (P < 0.001). Among those who did have a recent partner, 95% reported 
only 1 partner in the past 3 months, more than half (59%) stated that they last had sex in the 
past week, and 63% of women reported using a condom during this encounter compared 
with 77% of men (P < 0.001). Reported condom use at last sex was significantly associated 
with reporting that the clinic provided condoms among both women (OR, 1.7; 95% CI, 
1.17–2.35) and men (OR, 2.4; 95% CI, 1.18–4.82).
One quarter (23%) of participants had been newly diagnosed as having HIV in the past year. 
Among all participants, 76% were currently on ART, including 91% of those with CD4 T-
lymphocyte counts less than 250 cells/mm3. Women had higher median CD4 T-lymphocyte 
counts than did men (344 vs 326 cells/mm3, respectively; P = 0.047). Men were more likely 
than women to be on cotrimoxazole (67% vs 59%, respectively; P < 0.001).
Prevalence of STI
Among the 1063 HIV-infected women, 10.9% (95% CI, 7.8–14.0) had an etiologic diagnosis 
of trichomoniasis. Seventeen women were diagnosed as having gonorrhea, 6 with 
chlamydia, and 3 with syphilis. Only 6 women had 2 of these STI diagnosed concurrently. 
The 598 HIV-infected men in our study had significantly lower prevalences of most STI 
when compared with women. Only 2.8% (95% CI, 1.3–4.2) of men had laboratory-
confirmed trichomoniasis. Five men were diagnosed as having urethral gonorrhea and 5 with 
syphilis; no men had chlamydia or more than 1 of these STIs.
Among the 68 participants from whom genital ulcer swabs were collected, HSV-1 was 
detected in 3 of these swabs, HSV-2 was detected in 46, and T. palladium was detected in 1. 
Eighteen specimens were negative for the 3 pathogens studied.
Individuals who reported any sex partner in the past 3 months likely represent individuals at 
higher risk for recent infection. We found somewhat higher prevalences in this subgroup—
for example, the prevalence of trichomoniasis was 12.3% (95% CI, 8.5–16.1) among women 
and 3.4% (95% CI, 1.4–5.4) among men.
Correlates of Trichomoniasis Diagnosis Among Women
Among women, we explored correlates of laboratory-confirmed trichomoniasis diagnosis 
(Table 2). Younger age, lower education level, and diagnosis of HIV within the past year 
were significantly associated with higher prevalence of trichomoniasis. In the multiple 
regression model (Table 2), younger age and lower education level remained independently 
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associated with trichomoniasis. Similarly, the association of recent HIV diagnosis remained 
independently associated with trichomoniasis, after adjusting for age.
There were no significant regional differences in trichomonas prevalence among women. 
The provinces with the highest prevalence among women were Nyanza (14.1%) and Coast 
(12.3%) (Fig. 1).
DISCUSSION
This was the first large, representative study in sub-Saharan Africa to estimate the 
prevalence of multiple STIs and other genital infections among HIV-infected adults in HIV 
care programs. Approximately 11% of women had laboratory-confirmed trichomoniasis, but 
prevalences of other STIs—including gonorrhea, chlamydia, and syphilis—were relatively 
low (<1%–2%), consistent with relatively low levels of reported sexual risk behavior. In 
addition, 4% of individuals had genital ulcers, two thirds due to HSV-2. Currently, WHO 
recommends STI screening at enrollment into HIV programs,17 but many programs do not 
implement STI screening. Our study suggests that in large HIV care programs in Kenya, 
screening for trichomoniasis may be the most useful in women, whereas testing for other 
STIs might be less beneficial.
To our knowledge, there have been only 2 other large STI surveillance studies among HIV-
infected adults in sub-Saharan Africa, neither in HIV care programs. A 1993 to 1997 study 
of male factory workers in Zimbabwe found that HIV-positive men had an incidence of self-
reported STI syndromes (including urethral discharge, genital ulcer, and genital warts) of 
16.8 per 100 person-years.18 Because of the high-risk population and the self-reported 
approach to identifying STI, it is difficult to compare these findings with ours. The other 
study enrolled HIV-infected pregnant women in Malawi, Tanzania, and Zambia between 
2001 and 2003 and reported prevalence for trichomoniasis (18.8%), chlamydia (2.6%), 
genital ulcers (2.2%), and gonorrhea (1.7%).19 These prevalences were higher than what we 
observed. These differences may be attributable to regional or historic differences between 
populations, or to the greater likelihood of recent unprotected sex among pregnant women 
compared with our sample of HIV clinics, in which a third of participants reported no sexual 
partner in the past 3 months.
Similar to US-based studies of HIV-infected women,20 trichomoniasis had the highest 
prevalence among nonviral STIs assessed. Consistent with the broader epidemiology of 
trichomoniasis, we observed a lower prevalence among men than women. Among men, the 
consequences of infection are less severe. Among women, trichomoniasis can lead to birth 
complications including low birth weight and premature birth. Furthermore, among HIV-
infected women, trichomoniasis is associated with increased vaginal HIV shedding.20 
Consequently, a United States–based expert panel recommends periodic screening for 
trichomoniasis among HIV-infected women.21 In addition, a recent modeling study among 
HIV-infected women in the United States estimated that, in populations with a high 
prevalence of T. vaginalis, nearly a quarter of HIV infections transmitted from women to 
men are attributable to T. vaginalis co-infection in the female partner.22 Our study suggests 
that periodic screening for T. vaginalis in HIV programs in Africa may be beneficial.
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We noted an appreciable prevalence of genital ulcer disease (4%), mostly due to HSV-2. The 
World Health Organization recommends episodic acyclovir treatment to accelerate healing 
and decrease HIV shedding in ulcers.13 Genital ulcer disease may not be noted in routine 
follow-up at HIV care programs without examination or questions regarding ulcers. Our 
study yielded a lower prevalence of syphilis (<1%) compared with the Kenya AIDS 
Indicator Survey (4.2% among HIV-infected adults), a community-based survey.23 In 
contrast to our study of HIV care program attendees, most HIV-infected KAIS respondents 
were unaware of their HIV status. Participants in HIV care programs may have less risky 
sexual behavior than a community-based cohort. In addition, given their attendance in a 
clinic-based program, our participants may also have been more likely to receive treatment 
for symptomatic STI and routine cotrimoxazole prophylaxis, which may have some effect on 
bacterial STIs.
Consistent with other sub-Saharan African studies,19,24 we found that less education and 
younger age were independently associated with an increased risk of trichomoniasis in 
women. Antenatal surveillance data from South Africa have shown a significant association 
between lower educational attainment and HIV risk.25 This reflects a trend observed 
throughout Africa in which HIV risk transitioned from being associated with higher 
education early in the epidemic to an association with less education in more mature 
epidemics.26 Likewise, it is plausible that the least educated HIV-infected women lacked 
appropriate knowledge and awareness of risk or symptoms for other STI. A recent analysis 
of data pooled from 4 female microbicide trials also found that younger age was associated 
with multiple incident STI outcomes (although not trichomoniasis).27 Younger women with 
a higher likelihood of cervical columnar ectopy may be at increased risk for STI due to age-
discordant mixing, where younger women have older male partners, among whom STI 
prevalence is high. This pattern is consistent with other research from African that has found 
that age-discordant mixing is both prevalent28 and a risk factor for HIV infection.29 We did 
not collect data on partner age, so we were unable to look at age mixing directly in our data.
We found that a relatively high proportion of both HIV-infected women (65%) and men 
(78%) reported condom use at last sex. These estimates are consistent with estimates from a 
recent cross-sectional study of HIV-infected Kenyans living in the Kibera settlement, which 
found that 82% of men and 65% of women reported consistent condom use.30 We observed 
that women and men who reported availability of condoms at the HIV clinic had a 1.7- to 
2.4-fold increased likelihood of reporting condom use at last sex, suggesting that provision 
of condoms and advertising their availability may promote their use.
The primary strength of this study was the inclusion of a sample of the largest HIV care 
programs across Kenya. Coupled with the systematic sampling scheme, the STI prevalence 
estimates from this study are generalizable to HIV-infected adults receiving care at large 
facilities throughout Kenya. Our study protocol included etiologic testing for several STIs, 
which is superior to syndromic diagnosis that may fail to detect asymptomatic infections or 
lead to misclassification of STI. Finally, our study is relevant to prevention interventions in 
HIV care programs. We anticipate that our data will inform cost-effectiveness assessments to 
determine the merit of annual STI screening within HIV programs.
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Our study also has limitations. First, given the relatively low overall prevalence of STI we 
observed, we were unable to evaluate correlates of individual STI other than trichomoniasis 
in women. We used urine detection for male trichomoniasis and would have had higher 
detection with the addition of semen and urethral swabs.31 The purpose of our study was to 
determine the use of STI screening in HIV care programs; hence, we did not sample 
individuals in the community. We elected to broadly sampled large HIV programs, which 
represent most HIV-infected adults in care programs. It is possible that smaller clinics may 
have different STI prevalence; however, we do not have reasons to believe that STI 
prevalence in smaller clinics would differ. Finally, the sexual behavior measures we assessed 
may have been subject to social desirability bias if participants who engaged in high-risk 
sexual behaviors were less likely to report this. Similarly, social desirability bias may have 
influenced our observed association between condom provision and reported condom use.
Integrating STI treatment into routine HIV care may benefit individual health, and its 
potential impact on population-level transmission is undefined. Our study suggests that 
based on the STI prevalence among HIV-infected adults, annual screening for trichomoniasis 
in HIV-infected women might be beneficial. The relatively older ages of women in this study 
suggest that many younger women are not enrolled in HIV care, pointing to a gap in 
services. Presumably, many younger HIV-infected women diagnosed in prevention-of-
mother-to-child-transmission programs did not enroll in HIV care after delivery. Our data 
suggest that these women may benefit most from trichomoniasis screening. Further studies 
to determine relative benefits of targeted screening or syndromic management will be 
important to help HIV programs decide which approaches jointly and sustainably optimize 
individual, program, and population outcomes.
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Maps of participating clinics (A) and regional prevalence of trichomoniasis (B) among HIV-
infected women in HIV care programs throughout Kenya, 2010 (n = 1063).
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TABLE 1
Sociodemographic, Sexual Behavior, and HIV/Medical Characteristics of HIV-Infected Adults in HIV Care 
Programs Throughout Kenya, 2010 (n = 1661)
Characteristic
Women (n = 1063), Median 
(Range) or n (%)
Men (n = 598), Median (Range) 
or n (%) P
Sociodemographic
 Age, median (range), y 35 (18–70) 40 (18–77) <0.001
 Currently married or cohabiting*, n (%) 536 (50.5) 476 (79.0) <0.001
 Primary school education or less, n (%) 556 (55.6) 289 (48.9) 0.013
Sexual behavior, past 3 months
 ≥1 partner in past 3 mo, n (%) 587 (55.7) 399 (67.5) <0.001
 Current partner is spouse or live-in†, n (%) 409 (72.5) 361 (89.1) <0.001
 ≤1 wk since last sex†, n (%) 338 (57.2) 248 (60.6) 0.292
 Condom use at last sex†, n (%) 377 (63.2) 314 (76.6) <0.001
 Reported that clinic provided condoms, n (%) 560 (52.0) 381 (62.1) <0.001
Medical/HIV
 Diagnosed with HIV in last year, n (%) 228 (22.0) 142 (24.2) 0.320
 Current ART use, n (%) 773 (74.9) 453 (77.7) 0.322
  ART use if eligible, CD4 <350 cells/mm3‡, n (%) 773 (85.6) 453 (86.1) 0.817
  ART use if eligible, CD4 <250 cells/mm3‡, n (%) 773 (91.6) 453 (89.4) 0.186
 Cotrimoxazole use, n (%) 626 (58.9) 397 (66.9) 0.039
 CD4 count, median (range), cells/mm3 344 (0–1383) 326 (1–1368) 0.060




With most recent partner, among those who reported any partner in the past 3 months.
‡
ART eligibility is based on recent (<250 cells/mm3) and current (<350 cells/mm3) Kenyan national guidelines. Participants categorized as ART 
eligible if currently on ART or if current CD4 count was less than 250 or less than 350 cells/mm3.
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